A number of therapies for treating RET-altered lung and thyroid cancers have recently received FDA approval (e.g. selpercatinib and pralsetinib) and more are under investigation in several countries [39], including novel selective RET kinase inhibitors for medullary thyroid cancer that show promise in reducing the adverse effects associated with currently-used multikinase inhibitors [40]. This evidence concerns the gene RET and thyroid gland carcinoma.